Navigation Links
MEMOTEXT Collaborating with Johns Hopkins University To Evaluate Technology-Driven Adherence Programs
Date:1/13/2009

f Automated Dosing Reminders on Medication Adherence using HealthVault" Trial

This clinical trial will be completed in 14 months and in three phases: software development, a clinical research study, and subsequent data analysis. 500 subjects will be recruited in the U.S. for the two-part study, which includes a cohort study to assess baseline adherence with glaucoma medications followed by a randomized, controlled trial of the adherence intervention. Approximately 100 subjects will be randomized to participate in the technology-based adherence intervention program. The results of the study will be presented in a peer-reviewed forum upon completion of the trial, which is expected to conclude in mid-2010.

About Glaucoma and Adherence

Glaucoma is the second leading cause of blindness and visual disability worldwide. It's estimated that 2.5 million people in the U.S. are affected by glaucoma, with another 10 million undiagnosed. By the year 2010, worldwide, the number is predicted to be 60 million. Currently, there is no cure for glaucoma. However, studies have shown that reducing the eye pressure with topical medical therapy, office laser or surgery can prevent occurrence or slow disease progression. The majority of patients diagnosed with glaucoma or ocular hypertension are managed initially with medications. However, despite the availability of effective topical therapies, non-adherence in patients with glaucoma is poor and has been reported between 37-59%.

About MEMOTEXT

MEMOTEXT is a specialized healthcare application service provider focused on providing medication adherence intervention solutions. With over 25 years of expertise in patient-stakeholder issues and the telecommunications industry, MEMOTEXT integrates behavior modification, patient education and live support into the everyday lives of patients. MEMOTEXT uses proven methodologies and customized solutions that
'/>"/>

SOURCE MEMOTEXT Personalized Adherence Solutions
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related medicine news :

1. Pennsylvania Patient Safety Authority Launches New Website and Design With New Tagline Analyzing, Educating and Collaborating for Patient Safety
2. Four Abstracts by Biopure and Collaborating Scientists Accepted for Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
3. Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
4. Johnson & Johnson Announces Receipt of Israeli Antitrust Approval for Acquisition of Omrix
5. YMCA of the USA Expands Healthy Communities Initiatives With $6.8 Million Grant from the Robert Wood Johnson Foundation
6. Johnson Matthey Medical Announces Expansion
7. Posit Science Invited to Speak at Johns Hopkins University About Cutting Edge Cognitive Training Interventions
8. Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity
9. Video: Magic Johnson Foundation and Abbott Call for Greater Prevention, Testing and Treatment on World AIDS Day
10. Johns Hopkins and Makerere University to collaborate on African health education initiative
11. Johnson & Johnson Begins Tender Offer to Acquire Omrix
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... T1 (GSTT1) null genotypes have been linked to increased ... between GSTM1 and GSTT1 null genotypes and the risk ... of previous reports are limited by their small sample ... with the risk of GC and CRC need to ... , A research article to be published on ...
(Date:12/17/2009)... University of Jerusalem Kuvin Center for the Study ... $5 million grant from the Bill & Melinda ... Ethiopia. , The project will be led by ... the Institute of Medical Research Israel-Canada at the ... entitled ,Studies on the ecology and transmission dynamics ...
(Date:12/17/2009)... infection employed by Salmonella has to be ... group "Cytoskeleton Dynamics". The group,s results have now been ... " Cellular Microbiology ". , Salmonella are ... and absence of oxygen and thus propagate in the ... egg dishes such as mayonnaise or raw milk products ...
(Date:12/17/2009)... cells that could one day provide therapeutic options for ... the tissue of the umbilical cord, just as the ... treat some blood disorders, said University of Pittsburgh School ... of the Journal of Biomedicine and Biotechnology . ... to greater number, are remarkably stable and might not ...
(Date:12/17/2009)... recluse at times, researcher says , , THURSDAY, Dec. ... he has identified the illness that caused the ... headaches and skin problems for most of his ... have been suggested for the illness that could ... virtual recluse for periods of time. These include ...
Breaking Medicine News(10 mins):Health News:Hebrew U. receives $5 million for research on leishmaniasis in Ethiopia 2Health News:Invasion without a stir 2Health News:Umbilical cord could be new source of plentiful stem cells, say Pitt researchers 2Health News:New Theory Emerges on Darwin's Illness 2
... why some people feel the constant need to urinate ... has received a prestigious new 420,000 award from the leading ... the UK and the Netherlands have teamed up to take ... in Newcastle upon Tyne and Maastricht by Professor James Gillespie ...
... Pediatric Groups Select Intergy by Sage, TAMPA, Fla., ... Idaho to New Jersey -- have recently selected Intergy ... According to,representatives from each practice, the solution set provides ... practices recently signed onto Intergy EHR by Sage as ...
... ImmunoVaccine Technologies Inc. (IVT),a Nova Scotia-based ... binding,memorandum of understanding to acquire Immunotope ... products,for the treatment and prevention of ... acquisition will bring together IVT,s signature ...
... Inc. (OTC,Bulleitn Board: BSML), a leading provider of state-of-the-art ... at its spas, today announced several changes in its,management ... entry into a new,support services agreement., Effective December ... Chief,Executive Officer and a Director of BSML., Effective ...
... ATLANTA Oregon Health & Science University Cancer Institute researcher ... that are candidates for targeted therapy in acute myeloid leukemia ... This research will be presented at the American Society of ... 8:15 a.m. , This functional assay, called ...
... Recommendation From One Proxy Advisory Firm, MONTVALE, ... ) today issued a statement strongly recommending shareholders,re-elect ... and William,L. Asmundson - and reject Ramius Capital,s ... 2007 Annual Meeting of Shareholders., Robert Klatell, ...
Other Medicine News:Health News:International team gets new award to research the causes of bladder problems 2Health News:Pediatric Practices Select Intergy EHR by Sage for Electronic Health Records 2Health News:Pediatric Practices Select Intergy EHR by Sage for Electronic Health Records 3Health News:Pediatric Practices Select Intergy EHR by Sage for Electronic Health Records 4Health News:ImmunoVaccine Technologies Inc. to Acquire Immunotope Inc. 2Health News:BSML Announces Changes in Management 2Health News:BSML Announces Changes in Management 3Health News:BSML Announces Changes in Management 4Health News:OHSU Cancer Institute researcher develops test for targeted therapy in acute myeloid leukemia 2Health News:Datascope Recommends Shareholders Re-Elect its Two Incumbent Directors and Reject Ramius' Opposition Slate 2Health News:Datascope Recommends Shareholders Re-Elect its Two Incumbent Directors and Reject Ramius' Opposition Slate 3Health News:Datascope Recommends Shareholders Re-Elect its Two Incumbent Directors and Reject Ramius' Opposition Slate 4Health News:Datascope Recommends Shareholders Re-Elect its Two Incumbent Directors and Reject Ramius' Opposition Slate 5
(Date:12/17/2009)... Dec, 17 Connectyx Technologies Holding Group ... has formed a distribution partnership with United States ... Diabetic Supplies, Respiratory Supplies and Medications as well ... Dysfunction System. ,, Terms of the partnership were ... that, "This partnership adds to our growing distribution ...
(Date:12/17/2009)... -- Instacare Corp. (OTC Bulletin Board: ISCR) a ... drugs and diagnostics and at home testing products ... and provider of e-health technologies and revolutionary cell ... as part of the preparation of its Fiscal ... two new Directors and has rejected, as unneeded, ...
(Date:12/17/2009)... N.C., Dec. 17 Pharmaceutical Institute today ... GeneEd, Inc., a company specializing in life science ... e-courses, help expand Pharmaceutical Institute,s already extensive library ... is a leading provider of specialized training solutions ... subsidiary of Campbell Alliance. Financial terms of ...
Breaking Medicine Technology:Connectyx Announces Distribution Partnership with United States Medical Supply 2Connectyx Announces Distribution Partnership with United States Medical Supply 3Instacare Corp. Board of Directors Sets Growth Plans for 2010 2Pharmaceutical Institute Acquires E-Learning Assets from GeneEd, Inc. 2Pharmaceutical Institute Acquires E-Learning Assets from GeneEd, Inc. 3Nanogea Announces New Scientific Advisory Board Members 14402 1Nanogea Announces New Scientific Advisory Board Members 14402 2Nanogea Announces New Scientific Advisory Board Members 14402 3Breathe Safely LLC 3A Making Respirators 270 25 More Effective 59186 1Breathe Safely LLC 3A Making Respirators 270 25 More Effective 59186 2Chews 4 Health Dietary Supplements to be Featured on 26apos 3BBeauty Spaces 26apos 3B 59181 1Chews 4 Health Dietary Supplements to be Featured on 26apos 3BBeauty Spaces 26apos 3B 59181 2Chews 4 Health Dietary Supplements to be Featured on 26apos 3BBeauty Spaces 26apos 3B 59181 3
... Fuisz Tobacco today,announces the results of a ... the use of Fuisz Tobacco,s dissolving tobacco,strip and ... -- the study,s control., (Photo: http://www.newscom.com/cgi-bin/prnh/20080115/CLTU066 ... bioavailability for the,Fuisz Tobacco strip. A Fuisz Tobacco ...
... Placebo-Controlled Study Results Published in May 20 ... May 20 Eisai Corporation of North,America ... study in,Neurology that found patients with Lennox-Gastaut ... rufinamide as adjunctive,therapy experienced more than 40% ...
Other Medicine Technology:Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product 2Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product 3Data Show Rufinamide, an Investigational Adjunctive Treatment for Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40% 2Data Show Rufinamide, an Investigational Adjunctive Treatment for Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40% 3
... is intended for use in the clinical ... known concentration for monitoring assay conditions in ... Control with patient serum specimens when assaying ... user can compare observations with expected ranges ...
The K-ASSAY Lp(a) Control Set is intended for use as an assayed quality control material for monitoring the performance of Lp(a) immunoturbidimetric assays....
The K-ASSAY Anti-Streptolysin O Control Set is intended to be used as a consistent test sample of known concentration for monitoring the performance of K-ASSAY immunoturbidimetric assay for quantifyi...
... test is a rapid chromatographic immunoassay for ... A and B viral antigens from nasopharyngeal ... The Directigen EZ Flu A+B test is ... viral antigens can be distinguished from influenza ...
Medicine Products: